BYD And 2 Other SEHK Growth Stocks With Significant Insider Ownership

In This Article:

Amid a backdrop of fluctuating global markets, Hong Kong's Hang Seng Index has shown resilience, climbing 2.77% recently. This buoyancy in the market provides an intriguing context for examining growth companies with substantial insider ownership, which often suggests confidence from those who know the company best.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

iDreamSky Technology Holdings (SEHK:1119)

20.2%

104.1%

Pacific Textiles Holdings (SEHK:1382)

11.2%

37.7%

Fenbi (SEHK:2469)

32.8%

43%

Tian Tu Capital (SEHK:1973)

34%

70.5%

Adicon Holdings (SEHK:9860)

22.4%

28.3%

DPC Dash (SEHK:1405)

38.2%

90.2%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.7%

79.3%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

100.1%

Beijing Airdoc Technology (SEHK:2251)

28.7%

83.9%

Ocumension Therapeutics (SEHK:1477)

23.1%

93.7%

Click here to see the full list of 54 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

BYD

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BYD Company Limited operates in the automotive and battery sectors across China, Hong Kong, Macau, Taiwan, and internationally, with a market capitalization of approximately HK$777.07 billion.

Operations: The company's revenue is derived from its automotive and battery sectors across various regions including China, Hong Kong, Macau, Taiwan, and internationally.

Insider Ownership: 30.1%

BYD, a prominent growth company with high insider ownership in Hong Kong, is trading at 47.4% below its estimated fair value, signaling potential undervaluation. While its revenue growth forecast of 14.2% per year trails the significant 20% benchmark, its earnings are expected to outpace the local market with a 15.3% annual increase. Recent substantial sales and production increases reflect robust operational momentum, although no recent insider trading activity was reported to suggest shifts in internal confidence levels.

SEHK:1211 Earnings and Revenue Growth as at Jul 2024
SEHK:1211 Earnings and Revenue Growth as at Jul 2024

Shanghai INT Medical Instruments

Simply Wall St Growth Rating: ★★★★★☆

Overview: Shanghai INT Medical Instruments Co., Ltd. operates in the healthcare sector, specializing in the production and distribution of medical instruments, with a market capitalization of approximately HK$4.68 billion.

Operations: The company generates CN¥641.32 million from its cardiovascular interventional business.